Clinical Trials Directory

Trials / Completed

CompletedNCT02947841

The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients

The Effectiveness of Alternating Ventral Intermediate Nucleus Deep Brain Stimulation Parameters in Preventing Tolerance in Essential Tremor Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
22 (actual)
Sponsor
Oregon Health and Science University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the hypothesis that alternating DBS parameters on a weekly basis will prevent tolerance to stimulation and thus waning of benefit, compared with non-alternating stimulation. The primary endpoint will be preserved tremor control with the alternating group compared with standard treatment using the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS). Key secondary endpoints will be preserved activities of daily living measures as well as preserved tremor control as quantified by motion sensor data. This study has one primary aim: To determine if alternating DBS stimulation parameters on a weekly basis will be superior at preserving tremor control compared with usual stimulation (non-alternating stimulation) in ET patients with VIM DBS.

Conditions

Interventions

TypeNameDescription
OTHERAlternating stimulationTwo different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
OTHERPlaceboThe control cohort will receive Setting A but Setting B will be identical to Setting A.

Timeline

Start date
2016-10-01
Primary completion
2017-06-01
Completion
2017-07-01
First posted
2016-10-28
Last updated
2018-09-21

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02947841. Inclusion in this directory is not an endorsement.